- 1Division of Hematology/Oncology, Case Western Reserve University/University Hospitals of Cleveland.
- 2Pathology, Case Western Reserve University School of Medicine.
- 3Pathology, University Hospitals Case Medical Center.
- 4Dept of Epidemiology & Biostatistics, Case Western Reserve University.
- 5Hematology & Oncology, Case Western Reserve University.
- 6Hematology and Oncology, Case Western Reserve University afshin.dowlati@case.edu.
Abstract
CD30 is a cytokine receptor belonging to the tumor necrosis factor superfamily (TNFRSF8) that acts as a regulator of apoptosis. The presence of CD30 antigen is important in the diagnosis of Hodgkin's disease and anaplastic large cell lymphoma. There have been sporadic reports of CD30 expression in non-lymphoid tumors, including malignant mesothelioma. Given the remarkable success of brentuximab vedotin, an antibody-drug conjugate directed against CD30 antigen, in lymphoid malignancies, we undertook a study to examine the incidence of CD30 in mesothelioma and to investigate the ability to target CD30 antigen in mesothelioma. Mesothelioma tumor specimens (N = 83) were examined for CD30 expression by immunohistochemistry. Positive CD30 expression was noted in 13 mesothelioma specimens, primarily those of epithelial histology. There was no significant correlation of CD30 positivity with either tumor grade, stage or survival. Examination of four mesothelioma cell lines (H28, H2052, H2452, and 211H) for CD30 expression by both FACS analysis and confocal microscopy showed that CD30 antigen localized to the cell membrane. Brentuximab vedotin treatment of cultured mesothelioma cells produced a dose-dependent decrease in cell growth and viability at clinically relevant concentrations. Our studies validate the presence of CD30 antigen in a subgroup of epithelial-type mesothelioma tumors and indicate that selectedmesothelioma patients may derive benefit from brentuximab vedotin treatment.
No comments:
Post a Comment